GlucoMetrix plc aims to offer to all diabetic people a better quality of life.
The research on original gene-engineering procedures for recombinant human insulin is completed.
The new insulin promises better pharmaceutical effects, better compatibility and savings costs of approx. 60% in the production, being suitably particularly for diabetic patients, who have to fight with the therapy side effects.